Heron Therapeutics short interest was 31.36% of the float on August 14th, according to new data we received from Benzinga. Short interest totaled 46,738,152 shares, which was an increase of 8.08% from July 31st.
It is estimated that it would take 12.33 days for short sellers to buy back their shares, with current trading volumes.
Heron Therapeutics Hedge Fund Activity
We have seen 82 institutional investors add shares of Heron Therapeutics stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 10,239,225 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,192,403
- ORBIMED ADVISORS LLC removed 9,816,940 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,189,869
- PALISADE CAPITAL MANAGEMENT, LP removed 6,326,113 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,699,985
- MILLENNIUM MANAGEMENT LLC removed 3,560,426 shares (-46.7%) from their portfolio in Q2 2026, for an estimated $1,519,589
- D. E. SHAW & CO., INC. removed 2,884,205 shares (-96.0%) from their portfolio in Q2 2026, for an estimated $1,230,978
- MARSHALL WACE, LLP added 2,354,193 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,004,769
- CONGRESS PARK CAPITAL LLC removed 2,016,290 shares (-50.0%) from their portfolio in Q2 2026, for an estimated $860,552
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
